Description
KQB198 is an investigational medication currently being studied in clinical trials for advanced solid tumors, including colorectal cancer. It is being tested in combination with another investigational drug, KQB365, and sometimes with the established drug cetuximab. The trials are primarily focused on determining the safe dosage and evaluating the drug's effectiveness in shrinking tumors. These are early-phase trials (Phase 1), meaning the main goal is to assess safety and find the right dose, rather than definitively proving effectiveness. The trials are recruiting participants with advanced solid tumors, and specifically, one trial is looking at patients with colorectal cancer that has a specific type of KRAS mutation (G12S). The drug is given orally.
Mechanism of Action
KQB198 is being studied in combination with KQB365. The specific way KQB198 works (its molecular target or mechanism of action) is still being investigated in these early clinical trials. It is being tested alongside KQB365 to see if the combination is safe and effective against certain advanced solid tumors.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.